Table 1.

Group characteristics of patients started on first-generation antipsychotic long-acting injectable and second-generation antipsychotic long-acting injectable.

	SGA	FGA	p
Mean (SD) age, years	38.5 (11.7)	38.9 (12.7)	0.8
Sex (F/M)	65/92	65/92	1
Diagnosis (F20, F22, F25)	144, 2, 11	144, 2, 11	1
Mean (SD) time under the care of SLaM NHS Trust prior to index admission, years	4.95 (4.21)	3.97 (4.54)	0.048*
Mean (SD) number of inpatient and home treatment team days per year prior to index admission	8.23 (21.0)	14.46 (55.8)	0.62
Mean (SD) length of index admission, days	127.1 (204.1)	143.6 (213.2)	0.5
Ethnicity (African, Caribbean, Black, Mixed, British, Other White, Other)	45, 19, 39, 1, 33, 14, 6	45, 19, 39, 1, 33, 14, 6	1
Endpoint (none, medication stop or change, home treatment team, admission, death)	68, 15, 13, 55, 6	63, 9, 15, 68, 3	0.22

^*p < 0.05.

FGA, first-generation antipsychotic; F20 - Schizophrenia; F22 - Persistent Delusional Disorder; F25 - Schizoaffective Disorder; NHS, National Health Service; SGA, second-generation antipsychotic; SD, standard deviation; SLaM, South London and Mausley.